Advertisement

Long-term survival expectations of cancer patients in Europe in 2000–2002

Published:December 17, 2008DOI:https://doi.org/10.1016/j.ejca.2008.11.005

      Abstract

      Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000–2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. UK Department of Health. The NHS cancer plan: a plan for investment, a plan for reform. <http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4009609>; 2000 [accessed 25.11.07].

        • Haward R.A.
        The Calman–Hine report: a personal retrospective on the UK’s first comprehensive policy on cancer services.
        Lancet Oncol. 2006; 7: 336-346
      2. Berrino F, Capocaccia R, Coleman MP, et al., editors. Survival of cancer patients in Europe. The EUROCARE-3 study. Ann Oncol 2003;14(Suppl.):v9–155.

        • Berrino F.
        • De Angelis R.
        • Sant M.
        • et al.
        Survival of eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study.
        Lancet Oncol. 2007; 8: 773-783
        • Brenner H.
        • Gefeller O.
        An alternative approach to monitoring cancer patient survival.
        Cancer. 1996; 78: 2004-2010
        • Brenner H.
        • Hakulinen T.
        Up-to-date survival curves of patients with cancer by period analysis.
        J Clin Oncol. 2002; 20: 826-832
        • Brenner H.
        • Söderman B.
        • Hakulinen T.
        Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland.
        Int J Epidemiol. 2002; 31: 456-462
        • Talbäck M.
        • Stenbeck M.
        • Rosén M.
        Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data.
        Eur J Cancer. 2004; 40: 1361-1372
        • Brenner H.
        • Gefeller O.
        • Hakulinen T.
        Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications.
        Eur J Cancer. 2004; 40: 326-335
        • Verdecchia A.
        • Francisci S.
        • Brenner H.
        • et al.
        Recent cancer survival in Europe: a 2000–02 period analysis.
        Lancet Oncol. 2007; 8: 784-796
        • Ederer F.
        • Axtell L.M.
        • Cutler S.J.
        The relative survival rate: a statistical methodology.
        Natl Cancer Inst Monogr. 1961; 6: 101-121
        • Henson D.E.
        • Ries L.A.
        The relative survival rate.
        Cancer. 1995; 76: 1687-1688
        • Hakulinen T.
        Cancer survival corrected for heterogeneity in patient withdrawal.
        Biometrics. 1982; 39: 933-942
      3. SEER*Stat Release 6.3.6. <http://seer.cancer.gov/seerstat/> [accessed 25.11.07].

        • Corazziari I.
        • Quinn M.
        • Capocaccia R.
        Standard cancer population for estimating age standardized survival ratios.
        Eur J Cancer. 2004; 40: 2307-2316
        • De Angelis R.
        • Francisci S.
        • Baili P.
        • et al.
        • the EUROCARE Working Group
        The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis.
        Eur J Cancer. 2009; 45: 909-930
        • Sant M.
        • Capocaccia R.
        • Coleman M.P.
        • et al.
        Cancer survival increases in Europe, but international differences remain wide.
        Eur J Cancer. 2001; 37: 1659-1667
        • Coleman M.P.
        • Gatta G.
        • Verdecchia A.
        • et al.
        EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century.
        Ann Oncol. 2003; 14: v128-v149
        • Micheli A.
        • Coebergh J.W.
        • Mugno E.
        • et al.
        European health systems and cancer care.
        Ann Oncol. 2003; 14: v41-v60
        • Editorial
        Does the UK really have an effective cancer plan?.
        Lancet Oncol. 2007; 8: 747
        • Pinheiro P.S.
        • van der Heijden L.H.
        • Coebergh J.W.
        Unchanged survival of gastric cancer in the southeastern Netherlands since 1982: result of differential trends in incidence according to Laurén type and subsite.
        Int J Cancer. 1999; 84: 28-32
        • Brenner H.
        • Arndt V.
        • Stegmaier C.
        • Ziegler H.
        • Rothenbacher D.
        Is Helicobacter pylori infection a necessary condition for non-cardia gastric cancer?.
        Am J Epidemiol. 2004; 159: 252-258
        • Matysiak-Budnik T.
        • Mégraud F.
        • Lubczynska-Kowalska W.
        • et al.
        Helicobacter pylori infection in Eastern Europe: seroprevalence in the Polish population of Lower Silesia.
        Am J Gastroenterol. 1996; 91: 2513-2515
        • Lemmens V.E.
        • van Halteren A.H.
        • Janssen-Heijnen M.L.
        • Vreugdenhil G.
        • Repelaer van Driel O.J.
        • Coebergh J.W.
        Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity.
        Ann Oncol. 2005; 16: 767-772
        • Janssen-Heijnen M.L.
        • Maas H.A.
        • Houterman S.
        • Lemmens V.E.
        • Rutten H.J.
        • Coebergh J.W.
        Comorbidity in older surgical cancer patients: influence on patient care and outcome.
        Eur J Cancer. 2007; 43: 2179-2193
        • Proctor R.N.
        The global smoking epidemic: a history and status report.
        Clin Lung Cancer. 2004; 5: 371-376
        • Sant M.
        • Francisci S.
        • Capocaccia R.
        • Verdecchia A.
        • Allemani C.
        • Berrino F.
        Time trends of breast cancer survival in Europe in relation to incidence and mortality.
        Int J Cancer. 2006; 119: 2417-2422
        • Tyczynski J.E.
        • Plesko I.
        • Aareleid T.
        • et al.
        Breast cancer mortality patterns and time trends in 10 new EU member states: mortality declining in young women, but still increasing in the elderly.
        Int J Cancer. 2004; 112: 1056-1062
        • Vutuc C.
        • Waldhoer T.
        • Sevelda P.
        • Micksche M.
        • Haidinger G.
        Self-reported prostate cancer screening in Austria.
        J Med Screen. 2006; 13: 148-151
        • Patard J.J.
        • Tazi H.
        • Bensalah K.
        • et al.
        The changing evolution of renal tumours: a single center experience over a two-decade period.
        Eur Urol. 2004; 45: 490-493
        • Hennessy B.T.
        • Hanrahan E.O.
        • Daly P.A.
        Non-Hodgkin lymphoma: an update.
        Lancet Oncol. 2004; 5: 341-353
        • Pfreundschuh M.
        • Trumper L.
        • Osterborg A.
        • et al.
        CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
        Lancet Oncol. 2006; 7: 379-391
        • Brenner H.
        • Hakulinen T.
        Very long-term survival rates of patients with cancer.
        J Clin Oncol. 2002; 20: 4405-4409
        • Richards M.
        EUROCARE-4 studies bring new data on cancer survival.
        Lancet Oncol. 2007; 8: 752-753